Blog Posts

Lucky88 đưa tin: Thua 2 trận liên tiếp ở Trung Quốc, HLV U22 Việt Nam nói điều bất ngờ

Posted by Lucky88 on September 9, 2024 at 9:43pm 0 Comments

HLV Đinh Hồng Vinh thừa nhận việc trao cơ hội cho tối đa các cầu thủ vào sân thi đấu ở hai trận gặp U22 Trung Quốc và U22 Uzbekistan là nguyên nhân dẫn đến kết quả không tốt của U22 Việt Nam.



Xem thêm: https://lucky88.com/news/detail/na-uy-vs-ao-tip-bong-da-mien-phi-ngay-10092024



Chiều 7/9, U22 Việt Nam có trận đấu thứ hai tại giải giao hữu quốc tế CFA Team China 2024 ở Trung Quốc.… Continue

Delta Airlines and Alipay: A Seamless Travel Experience for Chinese Consumers

Posted by freeamfva on September 9, 2024 at 9:35pm 0 Comments

Delta Airlines and Alipay: A Seamless Travel Experience for Chinese Consumers

In recent years, the travel industry has seen a significant shift towards digital payments, with mobile payment platforms becoming increasingly popular. One such platform is Alipay, a leading online payment provider in China. Delta Airlines, recognizing the importance of catering to Chinese travelers, has partnered with Alipay to offer a seamless and convenient payment option for its customers. In this article,… Continue

Biosimilars Market to Rise Significantly from Key End-use Industry Sectors by 2030

Overall healthcare costs are rising owing to the high-priced pharmaceutical drugs, particularly biologics. Government bodies worldwide are concentrating on lower-priced drug synthesis. The United States spends the most on healthcare and is therefore, working on cutting down on the same. Likewise, price regulations in India and Japan for reducing the health budget have bolstered the demand for cost containment.

This scenario has thrown light on the requirement for new affordable and effective therapeutics, which can be favorable for the biosimilars industry in subsequent years. Market Research Future (MRFR) expects the biosimilars market to thrive at a rate of 7.5% from 2020 to 2027 (analysis period).

Popular biological drugs are edging towards patent cliff and this can mean substantial profits for the global market. oncology biosimilars, especially compared to the patented biologics and successful outcomes during clinical trials should also benefit the global market. The expanding pharmaceutical sector focused on developing biosimilar drugs can be another key growth booster in the near future.

Market Segmentation

Biosimilars industry can be considered with respect to product, applications, and end users.

By Products- wise

recombinant glycosylated proteins
recombinant peptides
recombinant non-glycosylated proteins

By Application-wise

caters to chronic diseases
oncology
blood disorders
autoimmune diseases
infectious diseases
growth hormone deficiency
Others

By End users

Hospitals
Clinics
Research institutes

Key Vendors

Top manufacturers of biosimilars in the global industry include Stada Arzneimittel AG (Germany), Teva Pharmaceuticals (Israel), Biocon (India), Pfizer (US), Sandoz International (Germany), Eli Lily & Company (US), Actavis, Inc. (US), Dr. Reddy’s Laboratories (India), Cipla Ltd (India), Amgen, Inc. (US), Samsung Biologics (South Korea), Hospira Inc.(US), Mylan, Inc.(US), Celltrion (South Korea), to mention a few.

Regional Status

Europe, MEA or Middle East & Africa along with the Americas, APAC or Asia Pacific are the primary markets for biosimilars.

The North American market displays a bright outlook and can emerge quite lucrative in the coming years, in view of the surging burden of chronic ailments in Canada and the United States. The rising spending on research activities by the healthcare agencies also fuels the market expansion in the region. Favorable reimbursement landscape in the region, especially in the US, encourages healthy competition as it results in lower incentives for the players to compete based on price.

Europe has taken the lead in the global market, as the region houses a vast elderly pool, with close to one fifth of the overall EU population aged more than 65 years. This has given way to several lifestyle-related disorders such as oncology, autoimmune diseases, diabetes, to name a few.

Presumably, the scenario has raised the demand for biosimilars and can mean higher market growth over the next few years. In addition to this, numerous blockbuster biologics are on track to lose patent in the coming years, which should present lucrative opportunities to the biosimilar manufacturers.

The APAC market is slated to witness considerable growth, with China, South Korea and India offering a host of lucrative opportunities for drug development as well as commercialization. These are generics-driven countries and are known for frequently launching new and advanced manufacturing platforms, which has brought down the costs associated with biosimilar production. In the coming few years, majority of the patent expiries is touted to be in biosimilars, which is deemed as a profitable aspect by leading manufacturers and can translate into substantial market growth.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Market Research Future (MRFR) team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York, New York 10013,
United States of America
+1 646 845 9312
Email: [email protected]

Views: 1

Comment

You need to be a member of On Feet Nation to add comments!

Join On Feet Nation

© 2024   Created by PH the vintage.   Powered by

Badges  |  Report an Issue  |  Terms of Service